MorphoSys (MOR)
(Delayed Data from NSDQ)
$18.55 USD
-0.25 (-1.33%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $18.61 +0.06 (0.32%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Price, Consensus and EPS Surprise
MOR 18.55 -0.25(-1.33%)
Will MOR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MOR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MOR
Novartis (NVS) Presents Positive Data on Renal Drugs at ERA
Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
MOR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
Novartis (NVS) to Undertake Job Cuts in Development Department
Other News for MOR
MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
Novartis AG Takes Major Stake in MorphoSys
IN BRIEF: Novartis to squeeze-out remaining MorphoSys shareholders
MorphoSys and Novartis sign delisting agreement
Novartis Aims for Full Acquisition of MorphoSys